CD8A and neoplasm: For example, an ionizable cationic lipid DLinDMA can act as a potent adjuvant for mRNA vaccines to induce robust TFH cell and GC B cell responses to generate neutralizing antibodies, while Toll-like receptor 7/8 (TLR7/8) agonist R848 can elicit an effective anti-tumor immunity by significantly enhancing the antigen-specific CD8+ T cells responses15,16.